Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MRUS
- Price
- 42.43
- Stock movement up
- +0.46 (1.10%)
- Company name
- Merus BV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.90B
- Ent value
- 2.61B
- Price/Sales
- 80.84
- Price/Book
- 4.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 19.24%
- 1 year return
- -1.53%
- 3 year return
- 13.53%
- 5 year return
- 30.55%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MRUS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 80.84 |
| Price to Book | 4.13 |
| EV to Sales | 72.73 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.46M |
| EPS (TTM) | -3.58 |
| FCF per share (TTM) | -2.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 35.93M |
| Gross profit (TTM) | -1.53M |
| Operating income (TTM) | -230.96M |
| Net income (TTM) | -244.56M |
| EPS (TTM) | -3.58 |
| EPS (1y forward) | -3.78 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -4.25% |
| Operating margin (TTM) | -642.76% |
| Profit margin (TTM) | -680.61% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 433.00M |
| Net receivables | 3.88M |
| Total current assets | 666.28M |
| Goodwill | 0.00 |
| Intangible assets | 1.86M |
| Property, plant and equipment | 22.46M |
| Total assets | 844.68M |
| Accounts payable | 6.18M |
| Short/Current long term debt | 1.76M |
| Total current liabilities | 80.08M |
| Total liabilities | 141.41M |
| Shareholder's equity | 703.26M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -153.91M |
| Capital expenditures (TTM) | 1.72M |
| Free cash flow (TTM) | -155.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.77% |
| Return on Assets | -28.95% |
| Return on Invested Capital | -34.60% |
| Cash Return on Invested Capital | -22.02% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 42.57 |
| Daily high | 42.57 |
| Daily low | 41.05 |
| Daily Volume | 617K |
| All-time high | 60.20 |
| 1y analyst estimate | 86.07 |
| Beta | 1.13 |
| EPS (TTM) | -3.58 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| MRUS | S&P500 | |
| Current price drop from All-time high | -29.52% | -12.04% |
| Highest price drop | -67.42% | -56.47% |
| Date of highest drop | 3 Apr 2020 | 9 Mar 2009 |
| Avg drop from high | -34.63% | -11.07% |
| Avg time to new high | 45 days | 12 days |
| Max time to new high | 1211 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.90B
Marketcap category
Mid-cap
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Employees
172
Website
Investor relations
-
SEC filings
CEO
Sven Ante Lundberg
Country
USA
City
Utrecht 3584
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page